inv(16)(p13;q22) leads to reciprocal fusion of CBFB and MYH11, with breakpoints located at intron 5 of CBFB and intron 5 of MYH11, and the fusion protein can lead to a reduction in active CBF;

The 2011 NCCN guidelines for AML risk grouping, showing that patients with inv(16) or t(16;16) chromosomal abnormalities have a better prognostic risk;

This probe specifically detects whether CBFB undergoes inter-fusion with MYH11.